StemRim has registered a patent in Mexico for the use of regenerative induction drug Redasemtide in cartilage disorders, indicating potential for future business expansion and medical applications. It is not expected to have a direct impact on the full-year financial results for the period ending July 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4599","jir_company_name":"StemRim","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-07-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4599-20260722-01.pdf","jir_short_summary":"StemRim has registered a patent in Mexico for the use of regenerative induction drug Redasemtide in cartilage disorders, indicating potential for future business expansion and medical applications. It is not expected to have a direct impact on the full-year financial results for the period ending July 2026.","jir_summary":"### Patent Registration and Business Expansion\nStemRim has registered a use patent for the regenerative induction drug Redasemtide in Mexico for cartilage disorders. This development secures the potential for expanding the drug\u2019s indications and developing new therapies, with expectations of future utilization in medical settings. The patent pertains to providing new treatment options for traumatic cartilage deficiency and osteoarthritis.\n\n### Future Outlook and Impact\nWhile this patent registration is not expected to have a direct impact on the consolidated financial results for the fiscal year ending July 2026, expanding drug indications may lead to future business growth and revenue generation. StemRim is advancing the development of pharmaceuticals that promote mobilization of bone marrow-derived mesenchymal stem cells via intravenous administration to facilitate cartilage repair, attracting attention for its upcoming clinical trials.","jir_financial_highlights":"Patent Registration Region: Mexico (New registration)\nApplication Number: MX\/a\/2021\/004758 (Unknown)\nRegistration (Publication) Number: To be decided (Unknown)","jir_category":"","jir_hashtags":"#StemRim, #PatentRegistration, #JapaneseStocks","jir_key_figures":"Patent Registration Region: Mexico\nApplication Number: MX\/a\/2021\/004758\nRegistration (Publication) Number: To be decided","jir_meta_title":"\u3010StemRim\u3011Cartilage Disorder Patent Registration | July 2026","jir_meta_description":"StemRim has registered a patent for regenerative induction drug applications in cartilage disorders in Mexico, demonstrating potential for business expansion. No impact on financial results for July 2026.","jir_og_title":"\u3010StemRim\u3011Cartilage Disorder Patent Registration | July 2026","jir_og_description":"StemRim registered a patent for cartilage disorder applications in Mexico, indicating potential for future business expansion and medical applications. No impact on the 2026 July period results.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58113,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-86506","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n